Welcome to our Alveolar Soft Part Sarcoma Library.

To read the full scientific reports, please click each one of the following subtitles:

Treatment options

• Value of repeat resections for survival in lung metastases from soft tissue sarcoma (Liebl et al. 2007)
• The new 1,318 nm Nd:YAG Laser system facilitates any kind of parenchymal lung resection in lobe sparing manner and in case of complete resection improves significantly the survival(Rolle et al. (1) 2006)
• Report: Surgeries for a total of 328 consecutive patients who had multiple lung metastases with a new 1318-nm Nd:YAG laser (Rolle et al. (2) 2006)
• Case studies of Alveolar Soft Part Sarcoma in MSKCC leads to the conclusion that practicing appropriate diagnostic techniques, aggressive surgical control of the primary tumor and long-term surveillance for metastases may result in long term survival (Kayton et al. 2006)
• Alveolar soft-part sarcoma responding to interferon alpha-2b (Roozendaal et al. 2003), case study.
• ASPS responds to intensive chemotherapy (Nickerson et al 2004), case study.
• Expression of Vascular Endothelial Growth Factor (VEGF) in ASPS and response to treatment with Avastin (bevacizumab) and interferon alpha-2b (Azizi et al. 2006), case study.

Potential ASPS Therapies

• TFE3 fusion gene activates MET signaling, indicating that ASPS is a target for therapeutic MET inhibition (Tsuda et al. 2007)

ASPS Clinical Studies

• Alveolar Soft Part Sarcoma - An Italian Study (Casanova et al. 2000)

• Alveolar Soft Part Sarcoma - A Japanese Study (Ogose et al. 2003)

• Alveolar Soft Part Sarcoma - An American/ Texas Study (Portera et al. 2000)

The Genetics of Alveolar Soft Part Sarcoma

• The chromosomal translocation in Alveolar Soft Part Sarcoma creates fusion between two genes: ASPL-TFE3 (Ladanyi et al. 2001)

• ASPL-TFE3 fusion is involved in ASPS, but also in Renal Cancer (Argani et al. 2001)

• The translocation of ASPS occurs in G2 of the cell cycle (Huang et al. 2005)

Gene expression studies of ASPS tumors

• Staining of ASPL-TE3 in tumors of TFE3 fusions (Argani et al. 2003)
• Immunostaining of TFE3 as a tool in the diagnosis of Alveolar Soft Part Sarcoma (Miller, 2003)
• Angiogenesis - Promoting Gene Patterns in Alveolar Soft Part Sarcoma (Lazar et al. 2007)
• Immunohistochemical discrimination between the ASPL-TFE3 fusion proteins of Alveolar Soft Part Sarcoma (Vistica et al. 2008)

June 2006: The cancer inducing activity of the gene MITF is demonstrated in clear cell sarcoma

This finding suggests that MITF and possibly other MITF related genes: TFE3, TFEB and TFEC serve as “oncogene engines” to induce cancer formation. TFE3 is the translocated gene, which is found in alveolar soft part sarcoma. Click here to read a commentary in EurekAlert. The original study was published in the Cancer Cell journal: Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers